Description: Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.
Home Page: www.springworkstx.com
SWTX Technical Analysis
100 Washington Boulevard
Stamford,
CT
06902
United States
Phone:
203 883 9490
Officers
| Name | Title |
|---|---|
| Mr. Saqib Islam J.D. | CEO & Director |
| Mr. Francis I. Perier Jr., M.B.A. | Chief Financial Officer |
| Dr. Badreddin Edris Ph.D. | Chief Operating Officer |
| Mr. Bhavesh Ashar | Chief Commercial Officer |
| Mr. Michael P. Nofi | Chief Accounting Officer |
| Ms. Kim Diamond | VP of Communications & Investor Relations |
| Mr. Herschel S. Weinstein J.D. | Gen. Counsel & Sec. |
| Mr. Daniel J. Pichl | Chief People Officer |
| Dr. L. Mary Smith PH.D. | Chief Devel. Officer |
| Dr. James Cassidy M.D., Ph.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Commodity Chemicals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.4437 |
| Price-to-Sales TTM: | 74.496 |
| IPO Date: | 1987-06-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 222 |